Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Acalabrutinib Tablet and Capsule
NCT04768985Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity at 48 hours, Area under the plasma concentration time curve from zero to the last quantifiable concentration at 48 hours and 1 more. Started Feb 2021; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04768985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768985.